伊维菌素作为新型补充性疟疾控制工具降低发病率和患病率:一项建模研究
该建模研究基于布基纳法索2015年整群随机试验的临床数据及2008-2013年布基纳法索、塞内加尔和利比里亚的昆虫学数据验证模型,模拟伊维菌素大规模给药在不同传播场景下对疟疾传播的影响。结果显示伊维菌素大规模给药可降低疟疾患病率和发病率,在高度季节性传播地区效果最显著,与季节性疟疾化学预防或双氢青蒿素-哌喹大规模给药联用可进一步大幅减少发病。
要点
- 伊维菌素大规模给药可降低疟疾发病率和患病率,高度季节性传播地区效果最佳。
- 在高度季节性中度传播地区,3轮伊维菌素大规模给药(3×300 μg/kg,间隔1月,覆盖率70%)预测降低临床发病71%、患病率34%。
- 在季节性疟疾化学预防基础上加用伊维菌素大规模给药,可额外降低5岁以下儿童临床发病77%。
核心结论
- 建模预测表明伊维菌素可成为疟疾控制工具箱的有价值补充,既适用于现有干预不足的持续高传播地区,也适用于接近消除地区以防止疫情复燃。
研究设计与样本
- 基于布基纳法索2015年整群随机试验的临床数据(伊维菌素给予身高超过90 cm的个体)以及2008-2013年布基纳法索、塞内加尔和利比里亚关于伊维菌素大规模给药治疗盘尾丝虫病或淋巴丝虫病后蚊虫结局的昆虫学数据,验证现有伊维菌素大规模给药对蚊群和疟疾传播影响的人群水平数学模型。
- 扩展模型以纳入一系列补充性疟疾干预(季节性疟疾化学预防和双氢青蒿素-哌喹大规模给药),并纳入关于更高剂量伊维菌素具有更长杀蚊效应的新数据。
- 考虑两种伊维菌素方案:单剂400 μg/kg(1×400 μg/kg)和连续三日每日300 μg/kg(3×300 μg/kg),在不同传播场景(高度季节性、季节性、常年性)的多种使用情景中模拟其效果,报告临床发病率和镜检患病率的百分比降低。
主要发现
- 在高度季节性中度传播场景中,3轮仅伊维菌素大规模给药(3×300 μg/kg,间隔1个月,覆盖率70%)预测降低临床发病率71%、患病率34%。
- 在该场景中,在季节性疟疾化学预防基础上加用伊维菌素大规模给药,与单独季节性疟疾化学预防相比,预测5岁以下儿童临床发病率额外降低77%。
- 在该场景中,在双氢青蒿素-哌喹大规模给药基础上加用伊维菌素大规模给药,与单独双氢青蒿素-哌喹大规模给药相比,预测全年龄组发病率额外降低75%、患病率额外降低64%。
关键数值与推荐
- 伊维菌素方案:单剂400 μg/kg(1×400 μg/kg)或连续三日每日300 μg/kg(3×300 μg/kg)。
- 高度季节性中度传播场景:3轮伊维菌素大规模给药(3×300 μg/kg,间隔1个月,覆盖率70%)预测降低临床发病率71%、患病率34%。
- 在季节性疟疾化学预防基础上加用伊维菌素大规模给药,5岁以下儿童临床发病率额外降低77%。
- 在双氢青蒿素-哌喹大规模给药基础上加用伊维菌素大规模给药,全年龄组发病率额外降低75%、患病率额外降低64%。
临床怎么用
- 伊维菌素大规模给药可作为疟疾控制的补充工具,尤其在高度季节性传播地区。
- 在现有干预(如季节性疟疾化学预防或双氢青蒿素-哌喹大规模给药)基础上加用伊维菌素大规模给药,可进一步降低疟疾发病和患病。
- 在持续高传播且现有干预不足的地区以及接近消除的地区,可考虑将伊维菌素大规模给药纳入综合疟疾控制策略。
局限性
- 该研究为建模研究,预测结果需在真实世界环境中进一步验证。
- 模型基于特定地区(布基纳法索、塞内加尔、利比里亚)的数据验证,外推至其他流行区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ivermectin is a potential new vector control tool to reduce malaria transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious. We aimed to estimate the effect of ivermectin on malaria transmission in various scenarios of use. METHODS: We validated an existing population-level mathematical model of the effect of ivermectin mass drug administration (MDA) on the mosquito population and malaria transmission against two datasets: clinical data from a cluster- randomised trial done in Burkina Faso in 2015 wherein ivermectin was given to individuals taller than 90 cm and entomological data from a study of mosquito outcomes after ivermectin MDA for onchocerciasis or lymphatic filariasis in Burkina Faso, Senegal, and Liberia between 2008 and 2013. We extended the existing model to include a range of complementary malaria interventions (seasonal malaria chemoprevention and MDA with dihydroartemisinin-piperaquine) and to incorporate new data on higher doses of ivermectin with a longer mosquitocidal effect. We consider two ivermectin regimens: a single dose of 400 μg/kg (1 × 400 μg/kg) and three consecutive daily doses of 300 μg/kg per day (3 × 300 μg/kg). We simulated the effect of these two doses in a range of usage scenarios in different transmission settings (highly seasonal, seasonal, and perennial). We report percentage reductions in clinical incidence and slide prevalence. FINDINGS: We estimate that MDA with ivermectin will reduce prevalence and incidence and is most effective in areas with highly seasonal transmission. In a highly seasonal moderate transmission setting, three rounds of ivermectin only MDA at 3 × 300 μg/kg (rounds spaced 1 month apart) and 70% coverage is predicted to reduce clinical incidence by 71% and prevalence by 34%. We predict that adding ivermectin MDA to seasonal malaria chemoprevention in this setting would reduce clinical incidence by an additional 77% in children younger than 5 years compared with seasonal malaria chemoprevention alone; adding ivermectin MDA to MDA with dihydroartemisinin-piperaquine in this setting would reduce incidence by an additional 75% and prevalence by an additional 64% (all ages) compared with MDA with dihydroartemisinin-piperaquine alone. INTERPRETATION: Our modelling predictions suggest that ivermectin could be a valuable addition to the malaria control toolbox, both in areas with persistently high transmission where existing interventions are insufficient and in areas approaching elimination to prevent resurgence. FUNDING: Imperial College Junior Research Fellowship.
引用
- Slater HC, Foy BD, Kobylinski K, et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infect Dis. 2020. PMID: 31948767. doi:10.1016/S1473-3099(19)30633-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。